Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized Placebo Controlled Study Of OSI-774 (TARCEVA) Plus Gemcitabine In Patients With Locally Advanced, Unresectable Or Metastatic Pancreatic Cancer

NCT00026338 is registered in ClinicalTrials.gov with NCIC Clinical Trials Group as lead sponsor.

NCT NCT00026338
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00026338 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized Placebo Controlled Study Of OSI-774 (TARCEVA) Plus Gemcitabine In Patients With Locally Advanced, Unresectable Or Metastatic Pancreatic Cancer
Lead sponsor
NCIC Clinical Trials Group
Phase
Phase 3
Overall status
Completed
Start date
October 29, 2001
Completion date
February 10, 2009
Enrollment
569 (actual)
Sites
173

Conditions

As the registry lists them; a condition with its own page is linked.

pancreatic cancer